REGN 2477

Drug Profile

REGN 2477

Alternative Names: REGN2477

Latest Information Update: 27 Feb 2017

Price : $50

At a glance

  • Originator Regeneron Pharmaceuticals
  • Class Antibodies; Monoclonal antibodies
  • Mechanism of Action Activin modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Fibrodysplasia ossificans progressiva; Musculoskeletal disorders

Most Recent Events

  • 19 Jun 2017 Regeneron Pharmaceuticals plans the LUMINA-1 phase II trial for Fibrodysplasia ossificans progressiva (NCT03188666)
  • 10 Feb 2017 REGN 2477 receives Orphan Drug status for Fibrodysplasia ossificans progressiva in USA before February 2017
  • 12 Jan 2017 Regeneron Pharmaceuticals completes a phase I trial in Healthy volunteers in Belgium (NCT02870400)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top